PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of mconcolMolecular & Cellular Oncology
 
Mol Cell Oncol. 2015 Oct-Dec; 2(4): e1024821.
Published online 2015 May 27. doi:  10.1080/23723556.2015.1024821
PMCID: PMC4905355

Role of hypoxia and vascular endothelial growth factors in lymphangiogenesis

Abstract

Hypoxia is a major condition for the induction of angiogenesis during tumor development but its role in lymphangiogenesis remains unclear. Blood and lymphatic vasculatures are stimulated by growth factors from the vascular endothelial family: the VEGFs. In this review, we investigate the role of hypoxia in the molecular regulation of synthesis of lymphangiogenic growth factors VEGF-A, VEGF-C, and VEGF-D. Gene expression can be regulated at transcriptional and translational levels by hypoxia. Despite strong regulation of DNA transcription induced by hypoxia-inducible factors (HIFs), the majority of cellular stresses such as hypoxia lead to inhibition of cap-dependent translation of the mRNA, resulting in downregulation of protein synthesis. Here, we describe how translation initiation of VEGF mRNAs is induced by hypoxia through an internal ribosome entry site (IRES)-dependent mechanism. Considering the implication of the lymphatic vasculature in metastatic dissemination, it seems crucial to understand the hypoxia-induced molecular regulation of lymphangiogenic growth factors to obtain new insights for cancer therapy.

Keywords: hypoxia, lymphangiogenesis, transcription, translation, VEGF

Abbreviations

ARE
(AU)-rich elements
CCL21
Chemokine (C-C motif) ligand 21
CCR7
C-C chemokine receptor type 7
DEAD
sequence D-E-A-D (asp-glu-ala-asp)
eIF
eukaryotic initiation factor
FGF
fibroblast growth factor
FLT
fms-related tyrosine kinase 4
HIF
Hypoxia-inducible factor
HRE
hypoxia response element
hnRNP
heterogeneous nuclear ribonucleoproteins
IRES
internal ribosome entry site
LEC
lymphatic endothelial cell MAPK, mitogen-activated protein kinases
ORF
open reading frame
PAIP2
poly(A) binding protein interacting protein 2
PDGF
platelet-derived growth factor
PGDH
prostaglandin dehydrogenase
PGE2
prostaglandin E2
SMC
smooth muscle cell
TTP
tristetrapolin
UTR
untranslated region
VEGF
vascular endothelial growth factor
VEGFR
vascular endothelial growth factor receptor

The Lymphatic Network

The lymphatic vasculature consists of a network of lymph vessels whose main function is to return interstitial protein-rich fluid back to the circulating blood. Fluid, macromolecules, and cells, such as leukocytes and activated antigen-presenting cells, enter the lymphatic system through the blind-ended lymphatic capillaries. From here, lymph is transported toward collecting lymphatic vessels and is returned to the blood circulation in the jugular area through the lymphatico-venous junctions.1 On its way, lymph is filtered through the lymph nodes, where foreign particles taken up by antigen-presenting cells are used to initiate specific immune responses.2 In the small intestine, lacteal lymphatic vessels inside the intestinal villi absorb the dietary fat released by enterocytes in the form of lipid particles called chylomicrons. In addition to these physiologic tasks, the lymphatic system participates in pathologic conditions such as lymphedema, inflammatory diseases, and tumor metastasis. Many studies have demonstrated the existence of proliferative peri- and intratumoral lymphatic vessels.3 Additionally, tumoral lymphangiogenesis correlates with an increase in metastases4,5 and detection of lymphangiogenic growth factors is associated with poor prognosis in many human tumors.6-8

Similar to blood capillaries, lymphatic capillaries are thin-walled, relatively large vessels composed of a single layer of endothelial cells, but they are not covered by pericytes or smooth muscle cells (SMCs) and have an absent or poorly developed basement membrane.9 In addition, they lack tight junctions and adherens junctions, which allow easy access for fluid, macromolecules, and cells into the vessel lumen.10 Initial lymphatics combine to form larger vessels called precollectors and collectors, which in turn lead to 4 major groups of lymph nodes in the axillary and inguinal regions. Endothelial cells of lymphatic capillaries are oak-leaf shaped and are characterized by discontinuous VE-Cadherin–positive button-like junctions. Collecting lymphatic vessels downstream have continuous zipper-like junctions previously described in blood vessels,9 a smooth muscle cell layer, basement membrane, and valves.

Lymphatic Markers

Lymphatic vessels were first described in the beginning of the seventeenth century; however, the first growth factors and molecular markers specific for these vessels were discovered only 10 to 15 years ago: Prox1, the main transcriptional factor implicated in lymphatic vasculature development,11 lymphatic vascular endothelial-cell hyaluronan receptor-1 (LYVE-1),12 a new homolog of the CD44 glycoprotein and a lymph-specific receptor for hyaluronan,13 and podoplanin, a transmembrane glycoprotein molecule.14 Although the blood and lymphatic vascular systems are structurally related and function in concert, these specific markers have allowed investigation of the unique features of lymph vessels. Vascular endothelial growth factor receptor (VEGFR)-3 (also known as FLT-4) has been described as an major marker of lymphatics15,16 because in the adult its expression becomes restricted to the lymphatic endothelium.17–19 However, recent findings have shown that VEGFR-3 is also upregulated on vascular endothelial cells in angiogenic sprouts and is present on vessels in tumors and wounds.20,21

Lymphangiogenesis in Pathology

In adult organisms, lymphangiogenesis takes place only in certain pathologic conditions. Abnormal function of the lymphatics is implicated in certain diseases, such as lymphedema, inflammation, immune diseases, and tumor metastasis.

Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities. When the lymphatic system has been damaged during surgery or radiation treatment, its capacity to absorb excess water and cells from the interstitial space is reduced. If the transport capacity is reduced such that it cannot handle this increase in lymphatic load, an insufficiency of the lymphatic system may occur. Lymphedema can be an unfortunate side effect of cancer treatment. It is a chronic condition that, if ignored, can lead to disfigurement, immobilization, and severe infections. Without treatment, the swelling may continue to increase.

Inflammation is thought to contribute to the development and progression of various cancers, including lung,22 breast,23 gastrointestinal,24-26 ovarian,27 prostate,28 skin,29 and liver cancers.30

Inflammatory breast cancer exhibits increased angiogenesis and lymphangiogenesis and has a higher metastatic potential than noninflammatory breast cancer.31 Blocking lymphangiogenesis in chronic inflammatory diseases may become an important means of ameliorating the severity of some of these pathologies.

The extent of lymph node metastasis is a major determinant for the staging and the prognosis of most human malignancies. Although the clinical significance of lymph node involvement is well documented, molecular mechanisms that promote tumor spread into the lymphatic or blood vascular systems and its widespread dissemination are not well understood. Recent studies have provided a large body of evidence indicating that newly visualized lymphatics facilitate formation of metastases. High tumor interstitial fluid pressure is thought to promote tumor cell entry into lymphatic vessels that have lower fluid pressure.32,33 Intratumoral lymphatic vessel growth often correlates with metastasis of human melanoma, breast, or head and neck cancers,34-36 in which tumor cells can be observed within lymphatic vessels, thus demonstrating that lymphatic vessel growth is important for tumor spread (Fig. 1).

Figure 1.
Hypoxic tumor cells (blue) near pre-existing blood and lymphatic vessels secrete (lymph)angiogenic growth factors such as vascular endothelial growth factor (VEGF)-A, -C, and –D to promote angiogenesis and lymphangiogenesis. Blood vessels bring ...

Tumor Growth, Hypoxia, and Lymphangiogenesis

As solid tumors grow in size, the cells within the expanding mass frequently become hypoxic because of the increasing distance from the nearest blood vessels. Thus, without an adequate vascular supply, solid tumors can grow only to a critical size of 1–2 mm (or approximately 106 cells), primarily due to lack of oxygen and nutrients.37 Therefore, a number of studies have been performed to characterize and then inhibit tumor angiogenesis. However, considering the hypoxia-induced regulation of lymphangiogenic factors it is crucial to regard tumor hypoxia and tumor lymphangiogenesis as 2 tightly interlocked phenomena. In contrast to blood vessels, the lymphatic vasculature does not promote tumor growth by providing key elements for cell survival (i.e., oxygen, nutrients) but allows metastatic dissemination of most solid tumors through the lymph nodes and finally to distant organs.38,39 The lymphatic network is not merely an alternative route into the blood vessels for dissemination but in fact constitutes the main vascular system implicated in dissemination as lymphatic vessels have an optimal structure for tumor cell invasion. Indeed, the main difference between the blood and lymphatic networks is the structure and permeability of their capillaries: the lymphatic capillaries are thin-walled, relatively large vessels, composed of a single layer of endothelial cells. In contrast to blood vessels, lymphatic capillaries are not ensheathed by pericytes or smooth muscle cells, and have little or no basement membrane.3 As a result of this high permeability, tumor cells can spread more easily in lymphatics than in blood vessels. This invasion is also not only a passive process as tumors induce new growth of lymphatic vessels in draining lymph nodes and enlargement of the lymphatic endothelium before metastasis. This remodeling of lymph nodes potentially contributes to the migration, implantation, or survival of metastatic tumor cells by inducing a specific tumor microenvironment. Thus, a hypoxic tumor will not only ensure its survival through activation of angiogenesis, but will also become more aggressive. This dual regulation of the blood and lymphatic vasculature by hypoxia during tumor growth also influences therapeutic options. First, there is a real crosstalk between tumor, blood, and lymphatic endothelial cells. Blood vessel endothelial cells produce lymphangiogenic factors such as VEGF-C, fibroblast growth factor (FGF)2, and platelet-derived growth factors (PDGFs) to facilitate tumor-induced lymphangiogenesis.40 Both endothelial cell types also produce matrix metalloproteinases that promote tumor spreading. Lymphatic endothelial cells (LECs) additionally express the CCL21 chemokine that is implicated physiologically in dendritic cell mobilization41 and interacts with the CCR7 receptor expressed by many tumors and thus stimulates lymphatic dissemination.42 Several treatments have been developed to specifically inhibit tumor angiogenesis (i.e., Avastin) and therefore suppress tumor oxygenation and so destroy tumor cells. However, the severe tumor hypoxia induced by these drugs induces overexpression of lymphangiogenic factors and increases lymphangiogenesis, thus increasing tumor dissemination. This collaboration between hypoxia and the 2 vascular systems to ensure tumor spreading can explain some of the failures of anti-angiogenic drugs in cancer treatment. Another striking difference between blood and lymphatic vasculature is that lymph vessels are often located in remote areas away from oxygen-carrying blood vessels and do not transport oxygen-carrying red blood cells. Therefore, a key feature of the lymphatic system is its hypoxic environment, and tumor cells have to adapt to this hostile environment in order to spread to the lymph nodes (Fig. 1).

Normoxia is defined as a milieu where the O2 concentration is sufficient to ensure the aerobic metabolism of cells, which is the basis of eukaryotic physiology.46 Hypoxia, in contrast, is an environment where the aerobic metabolism of cells is inhibited due to lack of oxygen. The major cellular response to hypoxia is stabilization of hypoxia-inducible factor 1 (HIF1). HIF1 is a transcription factor that controls the expression of a battery of more than 40 target genes.47-49 It is composed of an α subunit that is constitutively expressed and a β subunit that is subjected to rapid ubiquitination and proteasomal degradation under normoxic conditions.50 The molecular basis for this regulation is the O2-dependent hydroxylation of proline residues 402 and 564 in HIF-1α by any 1 of 3 enzymes in mammals that have been designated prolyl hydroxylase-domain proteins, or HIF-1α prolyl hydroxylases.51,52 Prolyl hydroxylation of HIF-1α is required for binding of the von Hippel–Lindau tumor suppressor protein (VHL), the recognition component of an E3 ubiquitin-protein ligase that targets HIF-1α for proteasomal degradation.53,54 Hypoxia has been shown to regulate not only angiogenesis but also lymphangiogenesis by promoting the overexpression of both specific lymphangiogenic factors (i.e., VEGF-C) and growth factors shared by the vascular and the lymphatic vasculature (i.e., VEGF-A, FGF2). Here, we provide an overview of the links between lymphangiogenic factors and hypoxia and the consequences of these relationships in a well-known hypoxic pathology—the development and dissemination of solid tumors.

Hypoxia-induced Molecular Regulation of VEGFs

The VEGF family is composed of growth factors involved in vascular development, including the vascular endothelial growth factors VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-E, and the placental growth factor.55 All members of this family stimulate proliferation and migration of endothelial cells in vitro. They bind and activate specific receptors on the endothelial cell surface: VEGF recognizes VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1); placental growth factor and VEGF-B recognize VEGFR-1; VEGF-C and VEGF-D recognize VEGFR-2 and VEGFR-3 (Flt-4). Lymphangiogenesis is induced by VEGFs that promote both angiogenesis (VEGF-A) and lymphangiogenesis (VEGF-C and VEGF-D).

Hypoxia-induced gene expression was first described as a transcriptional mechanism mediated by hypoxia-responsive elements present in the promoter regions of different genes that are targets of the hypoxia-induced HIF transcription factors. In particular, a functional hypoxia response element has been identified within the human 5´ flanking region of the VEGF-A gene56,57 that is the target of both HIF-1 and HIF-258 and allows transcriptional induction of VEGF-A by hypoxia in several physiologic (i.e., wound healing, inflammation) and pathologic (i.e., ischemia, tumor development) states.

In addition to its transcriptional effects, hypoxia also regulates gene expression post-transcriptionally, at the levels of mRNA stability and translation. An important class of mRNAs is stabilized by hypoxia: the so-called of AU-rich mRNAs, which possess AU-rich elements (AREs) in their 3´ untranslated regions (3´UTRs).59,60 AREs are found in most mRNAs coding for cytokines, growth factors, and proto-oncogenes (7–8% of the transcribed genome), indicating that the stabilization of such mRNAs in hypoxic conditions has drastic consequences on cell pathophysiology. In particular, angiogenic cytokines, including VEGF-A, are regulated by this mechanism.61 mRNA stabilization is controlled by the binding of the protein HuR to the ARE, in cooperation with polyA-binding protein interacting protein 2 (PAIP2).62 One proposed mechanism is that HuR acts through competition with destabilizing proteins such as AUF1 or tristetraprolin (TTP) for binding to the ARE.61 Another emerging concept is that HuR counteracts the binding of microRNAs to the mRNA 3´UTR.63 In the case of Vegfa mRNA, the HuR binding site overlaps with the binding site of miR-200b, thus HuR antagonizes the suppressive effect of this microRNA.63

Hypoxia also strongly regulates gene expression at the translational level. First, it silences global cell translation by inhibiting mRNA cap-dependent translation through inactivation of mTOR kinase, resulting in hypophosphorylation of the 4E-BP protein, which thus sequesters the cap-binding factor eIF4E.64,65 In addition, hypoxia induces phosphorylation of the initiation factor eIF2a by activation of PERK kinase, which also generates translational blockade.66 Two main alternative mechanisms are able to overcome this global translation inhibition induced by hypoxia: upstream open reading frames (uORFs) and internal ribosome entry sites (IRESs). uORFs are a key element of translational control in response to stress. These elements precede the initiation codon of the mRNA main coding region and are present in approximately 40–50% of mRNAs. They are mostly translational inhibitors when eIF2a is dephosphorylated and the complex of the initiator tRNA with eIF2 and GTP is available for translation initiation. In contrast, they allow the ribosome to scan and reach the initiation codon of the main coding sequence in conditions of stress, when eIF2a is phosphorylated.67

IRESs are RNA structural elements present in the 5´ non-translated regions of a small number of mRNAs that allow recruitment of the ribosome to a site that is a considerable distance from the cap structure, most frequently in the presence of trans-acting factors.64,68 The majority of identified IRESs are found in mRNAs of proteins that are associated with the control of cell growth and death, including growth factors, proto-oncogenes, and proteins required for apoptosis.65,69 IRES-dependent translation is cap-independent and, for cellular mRNAs, independent of eIF2a phosphorylation; this allows translation to occur in stress conditions.64,70 Notably, HIF1α mRNA itself possesses an IRES suggesting that these structures are crucial for translational regulation occurring under hypoxia. IRESs have also been identified in the mRNAs of 3 major lymphangiogenic growth factors, FGF2, VEGF-A, and VEGF-C.71,72 Interestingly, these 3 IRESs are activated in hypoxic conditions, resulting in translational induction of these factors.45,73 The regulation of VEGF-A and -C expression and their relationship with hypoxia is developed below.

VEGF-A

VEGF-A, which is also called vascular permeability factor, is a homodimeric glycoprotein with a molecular weight of approximately 45 kDa. At least 9 VEGF isoforms exist as a result of alternative patterns of splicing.74 Three of these, the VEGF isoforms of 121, 165, and 189 amino acids, are preferentially expressed by VEGF-A–producing cells.75-77 Each of the isoforms contributes to form a VEGF-A gradient essential for proper migration of endothelial cells (ECs) or LECs during (lymph)angiogenesis: the larger species, VEGF-165, VEGF-189 and VEGF-206, are basic and bind to isolated heparin and heparin proteoglycans distributed on cellular surfaces and extracellular matrices whereas the smaller species, VEGF-121, is acidic and freely diffusible (Fig. 2A).78 Although VEGF-A is primarily known as a growth factor that plays an essential role in physiologic and pathologic angiogenesis both during development and adulthood,79 it has been shown that it also has pro-lymphangiogenic properties.80,81 The pro-angiogenic activity of VEGF-A is mediated by interaction with a high-affinity VEGFR2 receptor, whereas the pro-lymphangiogenic activity is promoted by binding to the VEGFR2/R3 heterodimeric receptor.

Figure 2.
Schematic representation of vascular endothelial growth factor (VEGF)-A, -C, and -D mRNAs. (A) VEGF-A mRNA is characterized by a long 5´UTR (1,038nt) containing 2 internal ribosome entry sites (IRES; A and B). The VEGF-A gene encodes multiple ...

In addition to its transcriptional upregulation during hypoxia, VEGF-A is probably the most highly post-transcriptionally regulated factor.74 VEGF-A mRNA contains 2 IRESs72 and their structures have been predicted in silico (Fig. 2A). Each of these IRESs is located upstream from alternative initiation codons CUG and AUG responsible for the synthesis of alternative isoforms of VEGF-A.74 and both of them are activated by hypoxia.73 Vegfa IRESs are differently regulated by an upstream ORF, as well as by Mir16 bound to the 3´UTR.82,83 Study of VEGF-A IRES trans-acting factors suggest tight regulation, as both positive regulators activated by hypoxia (MAPK3 kinase) and negative regulators inhibited during this stress (DEAD-box RNA helicase 6) have been identified.84 Another mechanism implicated in translation regulation of VEGF-A is riboswitch, the ability of mRNAs to alter their folding structure and thus their rate of translation in response to environmental modification. During hypoxia, intracellular accumulation of hnRNP L promotes an active conformation and increases the rate of translation of VEGF-A mRNA.85 VEGF-A expression is strongly regulated at the level of mRNA stability, a process mainly mediated by the AREs present in the Vegfa mRNA. Indeed, the Vegfa mRNA is destabilized by several proteins including AUF1 and tristetraprolin (TTP), which target the AREs.61 Destabilization of Vegfa mRNA by TTP is responsible for the antiangiogenic effect of this protein.86 In contrast, Vegfa mRNA is stabilized by hypoxia.60 This process is mediated by binding of the RNA stabilizing protein HuR and its partner PAIP2 to the AREs, which prevents binding of the destabilizing proteins.60,61 Interestingly, the MDM2 protein, which is translocated from the nucleus to the cytoplasm under hypoxic conditions, also participates in Vegfa mRNA stabilization and allows an increase in Vegfa mRNA.87 Vegfa mRNA stability is thus controlled by an interplay between stabilizing and destabilizing proteins that compete for the AREs. Moreover, it has been proposed that Vegfa mRNA export from the nucleus and loading onto ribosomes can be increased during hypoxia by extra-nuclear shuttling of mRNA-binding proteins such as hnRNP L and A1, which also regulate Vegfa mRNA stability.88 Together, these mechanisms contribute to the transcriptional regulation induced by HIFs to allow a fast and massive overexpression of VEGF-A in response to hypoxia.

VEGF-C

The VEGF-C/VEGFR3 signaling pathway, identified in 1996,89 is the main pathway implicated in lymphangiogenesis. VEGF-C is produced as a precursor protein, which is activated by intracellular proprotein convertases.89,90 The secreted disulphide-linked VEGF-C subunits only bind VEGFR-3, but the factor is further proteolyzed in the extracellular environment by plasmin and other proteases to generate non–disulfide-linked homodimeric proteins with high affinity for both VEGFR-2 and VEGFR-3.3,90 VEGF-C is crucial for the induction of proliferation and migration and the survival of endothelial cells.91 VEGF-C is also an essential chemotactic and survival factor during embryonic lymphangiogenesis as homozygous deletion of VEGF-C leads to complete absence of the lymphatic vasculature in mouse embryos, whereas VEGF-C+/− mice display severe lymphatic hypoplasia. In VEGF-C null mice, lymphatic endothelial cells initially differentiate in the cardinal veins but fail to migrate and to form primary lymph sacs.92 Although several studies have shown positive correlations between HIF-1α and VEGF-C in various cancers93-95 the molecular mechanisms of hypoxia-induced regulation of VEGF-C remained poorly understood for a long time. Direct transcriptional regulation of VEGF-C by HIF-1α is unlikely as the promoter of VEGF-C does not contain an HRE sequence.96 Our recent work has demonstrated the existence of an IRES in the 5´UTR of both murine and human VEGF-C mRNA (Fig. 2B). As for the IRES of FGF2 and VEGF-A, VEGF-C IRES activity has been analyzed in vivo and we have demonstrated that VEGF-C IRES activity is upregulated during tumor growth in 3 murine models of carcinoma.45 Strikingly, we also observed that VEGF-C IRES activity increases under hypoxia in vitro but does not require the presence of HIF-1α in cells.

VEGF-D

VEGF-D, also called c-fos–induced growth factor, binds its receptor VEGFR-3 to promote lymphangiogenesis. The VEGF-D gene contains 7 exons (Fig. 2C). Maturation of VEGF-D is similar to that of VEGF-C and occurs by protein cleavage in N- and C-terminal regions. VEGF-D has been poorly studied due to the lack of phenotype generated by its invalidation in mice. Recent reports have shown that overexpression of VEGF-D induces tumor lymphangiogenesis and promotes lymphatic metastasis in mouse tumor models.97 However, few clinical studies have investigated the association between the expression of VEGF-D and lymphatic metastasis. VEGF-D overexpression correlates with an increase of lymphatic vessel growth and lymphatic metastasis.39 Recent studies suggest that VEGF-D is necessary for the entry of tumor cells into the lymphatic system for metastasis.98 VEGF-D promotes structural changes in tumor-draining lymphatic vessels and induces vasodilatation. VEGF-D also increases endothelial response to prostaglandin E2 (PGE2) by inhibiting the prostaglandin dehydrogenases (PGDHs).99,100

The role of hypoxia in promoting VEGF-D expression has not been clearly established. Recent studies have demonstrated correlations between VEGF-D and HIF-1α expression in invasive breast ductal carcinoma101 and in resected esophageal squamous cell carcinoma.102

These findings revealed that expression of lymphangiogenic factors is tightly linked to hypoxia, which is able to activate their expression at both transcriptional and translational levels. It is now well known that, at least in solid tumors, hypoxia is a major component of the tumor microenvironment and induces critical changes in tumor cell metabolism, angiogenesis, and lymphangiogenesis.

Concluding remarks and perspectives

The lymphatic vasculature has for a long time been considered the poor relation of the blood vasculature. Compared to the vascular network that provides both oxygen and nutrients, and is thus obviously necessary for life, the lymphatic system appeared to be a lesser vascular network. In addition, until recently it remained challenging to differentiate lymph from blood vessels due to a lack of specific markers. Recently, the lymphatic system has emerged as a vasculature that plays a crucial role in development and adulthood, and is not only implicated specifically in chronic inflammatory and vascular pathologies (psoriasis, lymphedema) but is also able to interact with blood vessels in cancer. Indeed, recent studies have highlighted the hypoxia-induced regulation of lymphangiogenic factor VEGF-C, demonstrating that understanding the molecular regulation of lymphangiogenesis in a wide range of organs and pathologies would offer a better understanding of such diseases and lead to new therapeutic solutions.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Jeltsch M, Tammela T, Alitalo K, Wilting J. Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res 2003; 314(1):69-84; PMID:12942362; http://dx.doi.org/10.1007/s00441-003-0777-2 [PubMed] [Cross Ref]
2. Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, Jeltsch M, Petrova TV, Pytowski B, Stacker SA, et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest 2005; 115(2):247-57; PMID:15668734; http://dx.doi.org/10.1172/JCI200522037 [PMC free article] [PubMed] [Cross Ref]
3. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005; 438(7070):946-53; PMID:16355212; http://dx.doi.org/10.1038/nature04480 [PubMed] [Cross Ref]
4. Williams CS, Leek RD, Robson AM, Banerji S, Prevo R, Harris AL, Jackson DG. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol 2003; 200(2):195-206; PMID:12754740; http://dx.doi.org/10.1002/path.1343 [PubMed] [Cross Ref]
5. Mumprecht V, Detmar M. Lymphangiogenesis and cancer metastasis. J Cell Mol Med 2009; 13(8A):1405-16; PMID:19583813; http://dx.doi.org/10.1111/j.1582-4934.2009.00834.x [PMC free article] [PubMed] [Cross Ref]
6. Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I, Ostoros G, Agocs L, Soltesz I, Dome B. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 2005; 11(20):7344-53; PMID:16243806; http://dx.doi.org/10.1158/1078-0432.CCR-05-1077 [PubMed] [Cross Ref]
7. Zeng Y, Opeskin K, Horvath LG, Sutherland RL, Williams ED. Lymphatic vessel density and lymph node metastasis in prostate cancer. Prostate 2005; 65(3):222-30; PMID:15948136; http://dx.doi.org/10.1002/pros.20288 [PubMed] [Cross Ref]
8. Stacker SA, Williams RA, Achen MG. Lymphangiogenic growth factors as markers of tumor metastasis. Apmis 2004; 112(7-8):539-49; PMID:15563315; http://dx.doi.org/10.1111/j.1600-0463.2004.apm11207-0812.x [PubMed] [Cross Ref]
9. Baluk P, Fuxe J, Hashizume H, Romano T, Lashnits E, Butz S, Vestweber D, Corada M, Molendini C, Dejana E, et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med 2007; 204(10):2349-62; PMID:17846148; http://dx.doi.org/10.1084/jem.20062596 [PMC free article] [PubMed] [Cross Ref]
10. Leak LV.. The structure of lymphatic capillaries in lymph formation. Fed Proc 1976; 35(8):1863-71; PMID:1269772 [PubMed]
11. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999; 98(6):769-78; PMID:10499794; http://dx.doi.org/10.1016/S0092-8674(00)81511-1 [PubMed] [Cross Ref]
12. Prevo R, Banerji S, Ferguson DJ, Clasper S, Jackson DG. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem 2001; 276(22):19420-30; PMID:11278811; http://dx.doi.org/10.1074/jbc.M011004200 [PubMed] [Cross Ref]
13. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999; 144(4):789-801; PMID:10037799; http://dx.doi.org/10.1083/jcb.144.4.789 [PMC free article] [PubMed] [Cross Ref]
14. Breiteneder-Geleff S, Soleiman A, Horvat R, Amann G, Kowalski H, Kerjaschki D. [Podoplanin-a specific marker for lymphatic endothelium expressed in angiosarcoma]. Verh Dtsch Ges Pathol 1999; 83:270-5; PMID:10714221 [PubMed]
15. Karkkainen MJ, Ferrell RE, Lawrence EC, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 2000; 25(2):153-9; PMID:10835628; http://dx.doi.org/10.1038/75997 [PubMed] [Cross Ref]
16. Kilic N, Oliveira-Ferrer L, Neshat-Vahid S, Irmak S, Obst-Pernberg K, Wurmbach JH, Loges S, Kilic E, Weil J, Lauke H, et al. Lymphatic reprogramming of microvascular endothelial cells by CEA-related cell adhesion molecule-1 via interaction with VEGFR-3 and Prox1. Blood 2007; 110(13):4223-33; PMID:17761831; http://dx.doi.org/10.1182/blood-2007-06-097592 [PubMed] [Cross Ref]
17. Breslin JW, Gaudreault N, Watson KD, Reynoso R, Yuan SY, Wu MH. Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism. Am J Physiol Heart Circ Physiol 2007; 293(1):H709-18; PMID:17400713; http://dx.doi.org/10.1152/ajpheart.00102.2007 [PubMed] [Cross Ref]
18. Bridenbaugh E.. Literature watch. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. Lymphat Res Biol 2005; 3(2):87-8; PMID:16000057; http://dx.doi.org/10.1089/lrb.2005.3.87 [PubMed] [Cross Ref]
19. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. Embo J 2001; 20(17):4762-73; PMID:11532940; http://dx.doi.org/10.1093/emboj/20.17.4762 [PubMed] [Cross Ref]
20. Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, Waltari M, Hellström M, Schomber T, Peltonen R, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454(7204):656-60; PMID:18594512; http://dx.doi.org/10.1038/nature07083 [PubMed] [Cross Ref]
21. Petrova TV, Bono P, Holnthoner W, Chesnes J, Pytowski B, Sihto H, Laakkonen P, Heikkilä P, Joensuu H, Alitalo K. VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell 2008; 13(6):554-6; PMID:18538738; http://dx.doi.org/10.1016/j.ccr.2008.04.022 [PubMed] [Cross Ref]
22. Ardies CM.. Inflammation as cause for scar cancers of the lung. Integr Cancer Ther 2003; 2(3):238-46; PMID:15035887; http://dx.doi.org/10.1177/1534735403256332 [PubMed] [Cross Ref]
23. Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004; 10(23):7965-71; PMID:15585631; http://dx.doi.org/10.1158/1078-0432.CCR-04-0063 [PubMed] [Cross Ref]
24. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 2001; 281(3):G626-34; PMID:11518674 [PubMed]
25. Brower V.. Researchers attempting to define role of cytokines in cancer risk. J Natl Cancer Inst 2005; 97(16):1175-7; PMID:16106019; http://dx.doi.org/10.1093/jnci/dji269 [PubMed] [Cross Ref]
26. Biarc J, Nguyen IS, Pini A, Gossé F, Richert S, Thiersé D, Van Dorsselaer A, Leize-Wagner E, Raul F, Klein JP, et al. Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S.bovis). Carcinogenesis 2004; 25(8):1477-84; PMID:14742316; http://dx.doi.org/10.1093/carcin/bgh091 [PubMed] [Cross Ref]
27. Altinoz MA, Korkmaz R. NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma 2004; 51(4):239-47; PMID:15254653 [PubMed]
28. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004; 61(1):60-72; PMID:15287094; http://dx.doi.org/10.1002/pros.20061 [PubMed] [Cross Ref]
29. Hussein MR, Ahmed RA. Analysis of the mononuclear inflammatory cell infiltrate in the non-tumorigenic, pre-tumorigenic and tumorigenic keratinocytic hyperproliferative lesions of the skin. Cancer Biol Ther 2005; 4(8):819-21; PMID:16210913; http://dx.doi.org/10.4161/cbt.4.8.1864 [PubMed] [Cross Ref]
30. Bartsch H, Nair J. Oxidative stress and lipid peroxidation-derived DNA-lesions in inflammation driven carcinogenesis. Cancer Detect Prev 2004; 28(6):385-91; PMID:15582261; http://dx.doi.org/10.1016/j.cdp.2004.07.004 [PubMed] [Cross Ref]
31. Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007; 13(10):2825-30; PMID:17504979; http://dx.doi.org/10.1158/1078-0432.CCR-06-2416 [PubMed] [Cross Ref]
32. Jain RK.. Barriers to drug delivery in solid tumors. Sci Am 1994; 271(1):58-65; PMID:8066425; http://dx.doi.org/10.1038/scientificamerican0794-58 [PubMed] [Cross Ref]
33. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002; 296(5574):1883-6; PMID:11976409; http://dx.doi.org/10.1126/science.1071420 [PubMed] [Cross Ref]
34. Dadras SS, Lange-Asschenfeldt B, Velasco P, Nguyen L, Vora A, Muzikansky A, Jahnke K, Hauschild A, Hirakawa S, Mihm MC, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 2005; 18(9):1232-42; PMID:15803182; http://dx.doi.org/10.1038/modpathol.3800410 [PubMed] [Cross Ref]
35. Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S, Ristamaki R. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 2003; 63(8):1920-6; PMID:12702584 [PubMed]
36. Choi WW, Lewis MM, Lawson D, Yin-Goen Q, Birdsong GG, Cotsonis GA, Cohen C, Young AN. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2005; 18(1):143-52; PMID:15297858; http://dx.doi.org/10.1038/modpathol.3800253 [PubMed] [Cross Ref]
37. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3(6):401-10; PMID:12778130; http://dx.doi.org/10.1038/nrc1093 [PubMed] [Cross Ref]
38. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7(2):192-8; PMID:11175850; http://dx.doi.org/10.1038/84643 [PubMed] [Cross Ref]
39. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7(2):186-91; PMID:11175849; http://dx.doi.org/10.1038/84635 [PubMed] [Cross Ref]
40. Petrova TV, Makinen T, Makela TP, Saarela J, Virtanen I, Ferrell RE, Finegold DN, Kerjaschki D, Ylä-Herttuala S, Alitalo K. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. Embo J 2002; 21(17):4593-9; PMID:12198161; http://dx.doi.org/10.1093/emboj/cdf470 [PubMed] [Cross Ref]
41. Tal O, Lim HY, Gurevich I, Milo I, Shipony Z, Ng LG, Angeli V, Shakhar G. DC mobilization from the skin requires docking to immobilized CCL21 on lymphatic endothelium and intralymphatic crawling. J Exp Med 2011; 208(10):2141-53; PMID:21930767; http://dx.doi.org/10.1084/jem.20102392 [PMC free article] [PubMed] [Cross Ref]
42. Issa A, Le TX, Shoushtari AN, Shields JD, Swartz MA. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res 2009; 69(1):349-57; PMID:19118020; http://dx.doi.org/10.1158/0008-5472.CAN-08-1875 [PubMed] [Cross Ref]
43. Ivanovic Z.. Hypoxia or in situ normoxia: The stem cell paradigm. J Cell Physiol 2009; 219(2):271-5; PMID:19160417; http://dx.doi.org/10.1002/jcp.21690 [PubMed] [Cross Ref]
44. Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 2008; 28(2):718-31; PMID:17967865; http://dx.doi.org/10.1128/MCB.01338-07 [PMC free article] [PubMed] [Cross Ref]
45. Morfoisse F, Kuchnio A, Frainay C, Gomez-Brouchet A, Delisle MB, Marzi S, Helfer AC, Hantelys F, Pujol F, Guillermet-Guibert J, et al. Hypoxia induces VEGF-C expression in metastatic Tumor cells via a HIF-1alpha-independent translation-mediated mechanism. Cell reports 2014; 6(1):155-67; PMID:24388748; http://dx.doi.org/10.1016/j.celrep.2013.12.011 [PubMed] [Cross Ref]
46. Ivanovic Z.. Physiological, ex vivo cell oxygenation is necessary for a true insight into cytokine biology. Eur Cytokine Netw 2009; 20(1):7-9; PMID:19318314 [PubMed]
47. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 1997; 272(38):23659-67; PMID:9295307; http://dx.doi.org/10.1074/jbc.272.38.23659 [PubMed] [Cross Ref]
48. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998; 12(2):149-62; PMID:9436976; http://dx.doi.org/10.1101/gad.12.2.149 [PubMed] [Cross Ref]
49. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. Embo J 1998; 17(11):3005-15; PMID:9606183; http://dx.doi.org/10.1093/emboj/17.11.3005 [PubMed] [Cross Ref]
50. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998; 95(14):7987-92; PMID:9653127; http://dx.doi.org/10.1073/pnas.95.14.7987 [PubMed] [Cross Ref]
51. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294(5545):1337-40; PMID:11598268; http://dx.doi.org/10.1126/science.1066373 [PubMed] [Cross Ref]
52. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, Ruiz de Almodovar C, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009; 136(5):839-51; PMID:19217150; http://dx.doi.org/10.1016/j.cell.2009.01.020 [PMC free article] [PubMed] [Cross Ref]
53. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292(5516):468-72; PMID:11292861; http://dx.doi.org/10.1126/science.1059796 [PubMed] [Cross Ref]
54. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292(5516):464-8; PMID:11292862; http://dx.doi.org/10.1126/science.1059817 [PubMed] [Cross Ref]
55. Ferrara N.. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9(Suppl 1):2-10; PMID:15178810; http://dx.doi.org/10.1634/theoncologist.9-suppl_1-2 [PubMed] [Cross Ref]
56. Pages G, Pouyssegur J. Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors. Cardiovasc Res 2005; 65(3):564-73; PMID:15664382; http://dx.doi.org/10.1016/j.cardiores.2004.09.032 [PubMed] [Cross Ref]
57. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16(9):4604-13; PMID:8756616 [PMC free article] [PubMed]
58. Blancher C, Moore JW, Talks KL, Houlbrook S, Harris AL. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 2000; 60(24):7106-13; PMID:11156418 [PubMed]
59. Gruber AR, Fallmann J, Kratochvill F, Kovarik P, Hofacker IL. AREsite: a database for the comprehensive investigation of AU-rich elements. Nucleic Acids Res 2011; 39(Database issue):D66-9; PMID:21071424; http://dx.doi.org/10.1093/nar/gkq990 [PMC free article] [PubMed] [Cross Ref]
60. Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996; 271(5):2746-53; PMID:8576250; http://dx.doi.org/10.1074/jbc.271.5.2746 [PubMed] [Cross Ref]
61. Griseri P, Pages G. Control of pro-angiogenic cytokine mRNA half-life in cancer: the role of AU-rich elements and associated proteins. J Interferon Cytokine Res 2014; 34(4):242-54; PMID:24697202; http://dx.doi.org/10.1089/jir.2013.0140 [PubMed] [Cross Ref]
62. Onesto C, Berra E, Grepin R, Pages G. Poly(A)-binding protein-interacting protein 2, a strong regulator of vascular endothelial growth factor mRNA. J Biol Chem 2004; 279(33):34217-26; PMID:15175342; http://dx.doi.org/10.1074/jbc.M400219200 [PubMed] [Cross Ref]
63. Chang SH, Hla T. Post-transcriptional gene regulation by HuR and microRNAs in angiogenesis. Curr Opin Hematol 2014; 21(3):235-40; PMID:24714527; http://dx.doi.org/10.1097/MOH.0000000000000040 [PubMed] [Cross Ref]
64. Holcik M, Sonenberg N. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 2005; 6(4):318-27; PMID:15803138; http://dx.doi.org/10.1038/nrm1618 [PubMed] [Cross Ref]
65. Baird SD, Turcotte M, Korneluk RG, Holcik M. Searching for IRES. RNA 2006; 12(10):1755-85; PMID:16957278; http://dx.doi.org/10.1261/rna.157806 [PubMed] [Cross Ref]
66. Silvera D, Schneider RJ. Inflammatory breast cancer cells are constitutively adapted to hypoxia. Cell Cycle 2009; 8(19):3091-6; PMID:19755858; http://dx.doi.org/10.4161/cc.8.19.9637 [PubMed] [Cross Ref]
67. Somers J, Poyry T, Willis AE. A perspective on mammalian upstream open reading frame function. Int J Biochem Cell Biol 2013; 45(8):1690-700; PMID:23624144; http://dx.doi.org/10.1016/j.biocel.2013.04.020 [PubMed] [Cross Ref]
68. Vagner S, Galy B, Pyronnet S. Irresistible IRES. Attracting the translation machinery to internal ribosome entry sites. EMBO Rep 2001; 2(10):893-8; PMID:11600453; http://dx.doi.org/10.1093/embo-reports/kve208 [PubMed] [Cross Ref]
69. Bushell M, Stoneley M, Sarnow P, Willis AE. Translation inhibition during the induction of apoptosis: RNA or protein degradation? Biochem Soc Trans 2004; 32(Pt 4):606-10; PMID:15270687 [PubMed]
70. Thakor N, Holcik M. IRES-mediated translation of cellular messenger RNA operates in eIF2alpha- independent manner during stress. Nucleic Acids Res 2012; 40(2):541-52; PMID:21917851; http://dx.doi.org/10.1093/nar/gkr701 [PMC free article] [PubMed] [Cross Ref]
71. Vagner S, Gensac MC, Maret A, Bayard F, Amalric F, Prats H, Prats AC. Alternative translation of human fibroblast growth factor 2 mRNA occurs by internal entry of ribosomes. Mol Cell Biol 1995; 15(1):35-44; PMID:7799942 [PMC free article] [PubMed]
72. Huez I, Creancier L, Audigier S, Gensac MC, Prats AC, Prats H. Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol 1998; 18(11):6178-90; PMID:9774635 [PMC free article] [PubMed]
73. Bornes S, Prado-Lourenco L, Bastide A, Zanibellato C, Iacovoni JS, Lacazette E, Prats AC, Touriol C, Prats H. Translational induction of VEGF internal ribosome entry site elements during the early response to ischemic stress. Circ Res 2007; 100(3):305-8; PMID:17255526; http://dx.doi.org/10.1161/01.RES.0000258873.08041.c9 [PubMed] [Cross Ref]
74. Arcondeguy T, Lacazette E, Millevoi S, Prats H, Touriol C. VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level. Nucleic Acids Res 2013; 41(17):7997-8010; PMID:23851566; http://dx.doi.org/10.1093/nar/gkt539 [PMC free article] [PubMed] [Cross Ref]
75. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246(4935):1309-12; PMID:2479987; http://dx.doi.org/10.1126/science.2479987 [PubMed] [Cross Ref]
76. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246(4935):1306-9; PMID:2479986; http://dx.doi.org/10.1126/science.2479986 [PubMed] [Cross Ref]
77. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266(18):11947-54; PMID:1711045 [PubMed]
78. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267(36):26031-7; PMID:1464614 [PubMed]
79. Carmeliet P.. Angiogenesis in life, disease and medicine. Nature 2005; 438(7070):932-6; PMID:16355210; http://dx.doi.org/10.1038/nature04478 [PubMed] [Cross Ref]
80. Dellinger MT, Brekken RA. Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium. PLoS One 2011; 6(12):e28947; PMID:22174934; http://dx.doi.org/10.1371/journal.pone.0028947 [PMC free article] [PubMed] [Cross Ref]
81. Wuest TR, Carr DJ. VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis. J Exp Med 2010; 207(1):101-15; PMID:20026662; http://dx.doi.org/10.1084/jem.20091385 [PMC free article] [PubMed] [Cross Ref]
82. Bastide A, Karaa Z, Bornes S, Hieblot C, Lacazette E, Prats H, Touriol C. An upstream open reading frame within an IRES controls expression of a specific VEGF-A isoform. Nucleic Acids Res 2008; 36(7):2434-45; PMID:18304943; http://dx.doi.org/10.1093/nar/gkn093 [PMC free article] [PubMed] [Cross Ref]
83. Karaa ZS, Iacovoni JS, Bastide A, Lacazette E, Touriol C, Prats H. The VEGF IRESes are differentially susceptible to translation inhibition by miR-16. RNA 2009; 15(2):249-54; PMID:19144909; http://dx.doi.org/10.1261/rna.1301109 [PubMed] [Cross Ref]
84. Casanova CM, Sehr P, Putzker K, Hentze MW, Neumann B, Duncan KE, Thoma C. Automated high-throughput RNAi screening in human cells combined with reporter mRNA transfection to identify novel regulators of translation. PLoS One 2012; 7(9):e45943; PMID:23029333; http://dx.doi.org/10.1371/journal.pone.0045943 [PMC free article] [PubMed] [Cross Ref]
85. Ray PS, Jia J, Yao P, Majumder M, Hatzoglou M, Fox PL. A stress-responsive RNA switch regulates VEGFA expression. Nature 2009; 457(7231):915-9; PMID:19098893; http://dx.doi.org/10.1038/nature07598 [PMC free article] [PubMed] [Cross Ref]
86. Essafi-Benkhadir K, Onesto C, Stebe E, Moroni C, Pages G. Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation. Mol Biol Cell 2007; 18(11):4648-58; PMID:17855506; http://dx.doi.org/10.1091/mbc.E07-06-0570 [PMC free article] [PubMed] [Cross Ref]
87. Zhou S, Gu L, He J, Zhang H, Zhou M. MDM2 regulates vascular endothelial growth factor mRNA stabilization in hypoxia. Mol Cell Biol 2011; 31(24):4928-37; PMID:21986500; http://dx.doi.org/10.1128/MCB.06085-11 [PMC free article] [PubMed] [Cross Ref]
88. Vumbaca F, Phoenix KN, Rodriguez-Pinto D, Han DK, Claffey KP. Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis. Mol Cell Biol 2008; 28(2):772-83; PMID:18039850; http://dx.doi.org/10.1128/MCB.02078-06 [PMC free article] [PubMed] [Cross Ref]
89. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo J 1996; 15(7):1751; PMID:8612600 [PubMed]
90. Karpanen T, Alitalo K. Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol 2008; 3:367-97; PMID:18039141; http://dx.doi.org/10.1146/annurev.pathmechdis.3.121806.151515 [PubMed] [Cross Ref]
91. Tammela T, Saaristo A, Lohela M, Morisada T, Tornberg J, Norrmén C, Oike Y, Pajusola K, Thurston G, Suda T, et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005; 105(12):4642-8; PMID:15746084; http://dx.doi.org/10.1182/blood-2004-08-3327 [PubMed] [Cross Ref]
92. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004; 5(1):74-80; PMID:14634646; http://dx.doi.org/10.1038/ni1013 [PubMed] [Cross Ref]
93. Liang X, Yang D, Hu J, Hao X, Gao J, Mao Z. Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res 2008; 28(3A):1659-66; PMID:18630523 [PubMed]
94. Schoppmann SF, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, Gnant M, Horvat R, Jakesz R, Birner P. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 2006; 139(6):839-46; PMID:16782443; http://dx.doi.org/10.1016/j.surg.2005.12.008 [PubMed] [Cross Ref]
95. Tao J, Li T, Li K, Xiong J, Yang Z, Wu H, Wang C. Effect of HIF-1alpha on VEGF-C induced lymphangiogenesis and lymph nodes metastases of pancreatic cancer. J Huazhong Univ Sci Technolog Med Sci 2006; 26(5):562-4; PMID:17219968; http://dx.doi.org/10.1007/s11596-006-0520-9 [PubMed] [Cross Ref]
96. Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, Joukov V, Alitalo K. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 1997; 272(40):25176-83; PMID:9312130; http://dx.doi.org/10.1074/jbc.272.40.25176 [PubMed] [Cross Ref]
97. Stacker SA, Achen MG. From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy. Lymphat Res Biol 2008; 6(3-4):165-72; PMID:19093789; http://dx.doi.org/10.1089/lrb.2008.1015 [PubMed] [Cross Ref]
98. Karnezis T, Shayan R, Caesar C, Roufail S, Harris NC, Ardipradja K, Zhang YF, Williams SP, Farnsworth RH, Chai MG, et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 2012; 21(2):181-95; PMID:22340592; http://dx.doi.org/10.1016/j.ccr.2011.12.026 [PubMed] [Cross Ref]
99. Karnezis T, Shayan R, Fox S, Achen MG, Stacker SA. The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget 2012; 3(8):893-906; PMID:23097685 [PMC free article] [PubMed]
100. Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer 2014; 14(3):159-72; PMID:24561443; http://dx.doi.org/10.1038/nrc3677 [PubMed] [Cross Ref]
101. Okada K, Osaki M, Araki K, Ishiguro K, Ito H, Ohgi S. Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. Anticancer Res 2005; 25(4):3003-9; PMID:16080559 [PubMed]
102. Tzao C, Lee SC, Tung HJ, Hsu HS, Hsu WH, Sun GH, Yu CP, Jin JS, Cheng YL. Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Dis Markers. 2008; 25(3):141-8; PMID:19096126; http://dx.doi.org/10.1155/2008/468323 [PMC free article] [PubMed] [Cross Ref]

Articles from Molecular & Cellular Oncology are provided here courtesy of Taylor & Francis